Clinical development of poly (ADP-ribose) polymerase (PARP) inhibitors for cases with homologous recombination repair (HRR) deficiency and immune therapies for cases with mismatch repair deficiency appear promising. Here, PARP1 is linked to mismatch repair cancer syndrome 1.